Hadi Hatoum
Critical Care Medicine · Conyers, GANPI 1891953378
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (57.6%), education and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Intuitive Surgical at 57.4% of the total. Among critical care medicine clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 153 payments — averaging $46.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- AstraZeneca$620
- GSK$481
- Boehringer Ingelheim$400
- Grifols USA, LLC$255
- Mylan Specialty L.p.$192
- plus $1K from 23 others
Across 1 payment — averaging $161.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$161
What the payments were for
- Travel & lodging$1,49421%
- Food & beverage$4,09258%
- Education$1,50421%
- Gifts$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 16 | $4,081 |
| AstraZeneca | 28 | $620 |
| GSK | 26 | $481 |
| Boehringer Ingelheim | 16 | $400 |
| Grifols USA, LLC | 11 | $255 |
| Mylan Specialty L.p. | 9 | $192 |
| Insmed, Inc. | 7 | $158 |
| Baxter Healthcare | 5 | $106 |
| Olympus America Inc. | 3 | $89 |
| Sanofi | 3 | $78 |
| Harmony Biosciences LLC | 3 | $72 |
| Viatris Specialty LLC | 3 | $69 |
| Actelion Pharmaceuticals US, Inc. | 3 | $67 |
| Verona Pharma, Inc. | 2 | $55 |
| Covis Pharma GmbH | 2 | $51 |
| Lilly USA, LLC | 2 | $45 |
| Jazz Pharmaceuticals Inc. | 1 | $35 |
| Coaptech, Inc. | 1 | $33 |
| AbbVie | 2 | $31 |
| Amgen | 1 | $26 |
| CSL Behring | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Genentech, Inc. | 1 | $21 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Merck | 1 | $18 |
| Electromed, Inc. | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $15 |
| Resmed Corp | 1 | $15 |
| La Jolla Pharmaceutical Company | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,733
- TAGRISSO$121
How this compares
$7,106 in reported general payments places this provider in the 90th percentile of 265 critical care medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 179 | $136,984 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 47 | $31,366 |
| EliquisApixaban | 25 | $24,099 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $17,469 |
| Spiriva HandihalerTiotropium Bromide | 20 | $14,790 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $7,494 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $6,125 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 184 | $5,838 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $2,709 |
| Ventolin HfaAlbuterol Sulfate | 33 | $2,563 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $1,957 |
| Wixela InhubFluticasone Propion/Salmeterol | 16 | $1,235 |
| Rifampin | 11 | $414 |
| Prednisone | 114 | $309 |
| Azithromycin | 64 | $215 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $481 | $161,947222 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $620 | $37,49161 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 265 critical care medicine providers in Georgia.
Other critical care medicine in Conyers
- Georges Al-HelouConyers$5K
- Kawanjit SurapurConyers$3K
- Rachna PatelConyers$2K
- Salman FidahusseinLagrange$852K
- Bruce FriedmanAugusta$629K
- Gregory MauldinSnellville$221K
- Ramzy RimawiAtlanta$72K
- Rafael Alba YunenBrunswick$58K
- April McDonaldGainesville$41K
- Matthew SchmittAtlanta$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.